Olmesan 20

Indications

Olmesartan is suitable for the treatment of mild to moderate essential hypertension. Olmesartan can be used alone or in combination with the diuretic thiazide.

 

Pharmacology

Olmesan 20 is a potent, orally active, selective angiotensin II receptor (type AT1) antagonist. Regardless of the source or route of synthesis of angiotensin II, it is expected to block all the effects of angiotensin II-mediated by AT1 receptors. Selective antagonism of the angiotensin II receptor (AT1) leads to an increase in plasma renin levels and angiotensin I and II concentrations, as well as a decrease in the plasma concentration of aldosterone. Angiotensin II is the main vasoactive hormone of the renin-angiotensin-aldosterone system (RAAS), which plays an important role in the pathophysiology of hypertension through type 1 (AT1) receptors.

 

 Dosage & Administration

Adults: the dosage must be individualized. The usual starting dose is 10 mg once a day. For patients whose blood pressure is not adequately controlled with the dose, the dose can be increased to 20 mg, once daily as the optimal dose. For patients who need to lower their blood pressure further after 2 weeks of treatment, the olmesartan dose can be increased to 40 mg. Doses greater than 40 mg do not appear to have a greater effect.

Pediatric Use: Safety and efficacy in pediatric patients have not been established. 

Use in the elderly: Of the total number of hypertensive patients who received Olmesan 20 in clinical studies, more than 20% were 65 years and years or older, and more than 5% were 75 years or older. No overall difference in efficacy or safety was observed between the elderly patient and the younger patients.

 

Interaction

In healthy volunteers, no significant drug interactions were reported in the study of olmesartan medoxomil combined with digoxin or warfarin. The bioavailability of Olmesartan was not significantly changed by the co-administration of antacids [Al (OH) 3 / Mg (OH) 2]. Olmesartan 
Medoxomil is not metabolized by the cytochrome P450 system and has no effect on P450 enzymes; therefore, it is not expected to interact with drugs that inhibit, induce, or be metabolized by these enzymes.

 

Contraindications

Olmesartan is contraindicated in patients who are allergic to any component of this product.

 

Side Effects

Common or very common: arthritis, chest pain, cough, fatigue, gastrointestinal disorders, hematuria, hypertriglyceridemia, hyperuricemia, flu-like symptoms, musculoskeletal pain, peripheral edema, pharyngitis, rhinitis, urine Road infection.  

Uncommon: angina, rash, dizziness.

Very rare: headache, myalgia, itching, thrombocytopenia, urticaria.

 

Pregnancy & Lactation

Pregnancy category C (early pregnancy) and D (second and third trimester)

 

Precautions & Warnings

Fetal / Neonatal Morbidity and Mortality: Drugs that act directly on the renin-angiotensin system can cause morbidity and death in pregnant women and newborns. angiotensin. When pregnancy is detected, Olmesan 20 should be stopped as soon as possible. 

Patients with low blood volume or saline insufficiency: In patients with activated renin-angiotensin system, such as patients with blood volume and/or saline insufficiency (for example, patients receiving high-dose diuretics), start using omega. treatment with Medoxomil Tan. Treatment should be started under close medical supervision. If hypotension occurs, the patient should be placed supine and an intravenous infusion of normal saline should be given if necessary.

 

Therapeutic Class

Angiotensin-ll receptor blocker

 

Storage Conditions

Keep out of the reach of children. Store the original packaging in a cool, dry place. Avoid light and avoid humidity.

 

Pharmaceutical Name

Beximco Pharma Ltd

 

Generic

Olmesartan Medoxomil

 

Related Products

• Abetis 20
• Olmesta 20